Literature DB >> 2513114

Balloon-occluded arterial infusion therapy in the treatment of primary and recurrent gynecologic malignancies.

Y Yamashita1, M Takahashi, H Bussaka, Y Korogi, R Saito, K Miyazaki, S Fujisaki, H Okamura.   

Abstract

Balloon-occluded arterial infusion (BOAI) of bilateral internal iliac arteries produces high drug concentration as well as increased arterial flow of pelvic organs. Twenty-seven patients with primary and locally recurrent gynecologic malignancies were treated with BOAI of cisplatinum. Six of 10 patients with primary advanced uterine cancer and 5 of 11 patients with recurrent cancer showed clinical response. In 6 patients, BOAI was performed as an adjuvant therapy to radiation or other chemotherapy. Toxicity was similar to that seen with systemic treatment using cisplatinum, but its frequency and degree were less severe.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513114     DOI: 10.1007/bf02577151

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  17 in total

Review 1.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

2.  Cis-platinum in advanced gynecologic malignancy.

Authors:  F B Stehman; S C Ballon; L D Lagasse; T P Chamorro; R C Donaldson; J A Roberts; L C Ford
Journal:  Gynecol Oncol       Date:  1979-06       Impact factor: 5.482

3.  Continuous pelvic arterial infusion with bleomycin for squamous carcinoma of the cervix recurrent after irradiation therapy.

Authors:  C P Morrow; P J DiSaia; C F Mangan; L D Lagasse
Journal:  Cancer Treat Rep       Date:  1977-10

4.  Hypogastric artery infusion and radiation therapy for advanced squamous cell carcinoma of the cervix.

Authors:  J P Smith; G E Randall; J R Castro; R D Lindberg
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1972-01

5.  cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.

Authors:  T Thigpen; H Shingleton; H Homesley; L LaGasse; J Blessing
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

6.  cis-Platinum in gynecologic cancer. III. Toxicity.

Authors:  D J Hall; R Diasio; D R Goplerud
Journal:  Am J Obstet Gynecol       Date:  1981-10-01       Impact factor: 8.661

7.  Bleomycin-adriamycin-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent cervical carcinoma.

Authors:  B Sorbe; B Frankendal
Journal:  Obstet Gynecol       Date:  1984-02       Impact factor: 7.661

8.  Experimental transcatheter intraarterial infusion-occlusion chemotherapy.

Authors:  J H Anderson; C Gianturco; S Wallace
Journal:  Invest Radiol       Date:  1981 Nov-Dec       Impact factor: 6.016

9.  Efficacy of "two-route chemotherapy" using intra-arterial cisplatin and iv sodium thiosulfate, its antidote, in rat bladder tumor.

Authors:  K Sagiyama; J Uozumi; K Aoki; T Baba
Journal:  Cancer Treat Rep       Date:  1983-06

10.  [Balloon occluded arterial infusion therapy for malignant hepatic tumors].

Authors:  M Kawabata; S Takashima; K Mitsuzane; M Tanaka; C Maeda; J Hamachi; S Nomura; M Toshiyuki; N Kobayashi; M Sato
Journal:  Gan To Kagaku Ryoho       Date:  1984-04
View more
  2 in total

1.  Extended intraarterial cisplatin infusion for treatment of gynecologic cancer after alteration of intrapelvic blood flow and implantation of a vascular access device.

Authors:  T Yamada; F Ohsugi; T Irie; C Ishii; S Sadaoka; S Tada
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

2.  Transcatheter arterial infusion therapy combined with radical hysterectomy in the treatment of advanced cervical cancer.

Authors:  Y Nagata; T Ishigaki; K Okajima; K Fujiwara; T Kinashi; M Mitumori; N Ooya; Y Kitakabu; M Hiraoka; M Abe
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Jan-Feb       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.